Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


MCL1 as a therapeutic vulnerability in Burkitt lymphoma

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: MCL-1 is constitutively over-expressed and a key molecular therapeutic vulnerability for Burkitt lymphoma (BL) and a subset of large B-cell lymphomas.
Fig. 2: BCL-XL functions as a switch to govern MCL-1 inhibitor (MCL-1i) resistance ex vivo and in vivo.

Data availability

The datasets analyzed during the current study are available in the Gene Expression Omnibus repository under access numbers GSE10172 and GSE4475.


  1. Mohammad Muhsin Chisti HK, Yadav SK. B-cell lymphoma. MedScape2018. 2021.

  2. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4:a014282.

    Article  Google Scholar 

  3. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43.

    Article  CAS  Google Scholar 

  4. Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387–93.

    Article  Google Scholar 

  5. Miles EF, Jacimore LL. Synchronous bilateral breast carcinoma and axillary non-hodgkin lymphoma: a case report and review of the literature. Case Rep Oncol Med. 2012;2012:685919.

    Google Scholar 

  6. Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167:394–401.

    Article  CAS  Google Scholar 

  7. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.

    Article  CAS  Google Scholar 

  8. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG-5961. Br J Haematol. 2010;148:600–10.

    Article  Google Scholar 

  9. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2:920–32.

    Article  CAS  Google Scholar 

  10. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.

    Article  CAS  Google Scholar 

  11. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leukemia. 2008;22:2226–9.

    Article  CAS  Google Scholar 

  12. Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood. 2012;119:3757–66.

    Article  CAS  Google Scholar 

  13. Fernandez-Marrero Y, Spinner S, Kaufmann T, Jost PJ. Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia. 2016;30:2152–9.

    Article  CAS  Google Scholar 

  14. Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Investig. 2018;128:5517–30.

    Article  Google Scholar 

  15. Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, et al. BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models. Cancer Cell. 2019;35:752–66.e9.

    Article  CAS  Google Scholar 

Download references


This work was supported by funds from the Florida State Live Like Bella Pediatric Cancer Research Initiative.

Author information

Authors and Affiliations



RY was responsible for generating all CRISPR/cas9 cells and protein overexpressing cells, performing western blot experiments, and interpreting data. MYW was responsible for performing and analyzing image based cell viability assays in cell lines and patient samples, other cell viability assays, editing the manuscript. CB was responsible for providing patient samples and providing feedback on the study. XZ was responsible for study conception and design, performing cell viability experiments, the in vivo study, performing the analysis on the GEO patient datasets and editing the manuscript. JT was responsible for conception and design of the study, analyzing and interpreting all data, writing and reviewing the manuscript, and providing administrative, technical, and material support.

Corresponding author

Correspondence to Jianguo Tao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yuan, R., Wang, M.Y., Bi, C. et al. MCL1 as a therapeutic vulnerability in Burkitt lymphoma. Leukemia (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:


Quick links